Applying quality by design (QbD) concept for fabrication of chitosan coated nanoliposomes

Journal of Liposome Research

Volumn 24, Issue 1, 2014, Pages 37-52

  Pandey, Abhijeet P ^a   Karande, Kiran P ^a   Sonawane, Raju O ^a   Deshmukh, Prashant K ^a  

^a H R PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Critical processing parameters; Critical quality attributes; Design space; Ishikawa diagrams; Tramadol

Indexed keywords

CHITOSAN; CHITOSAN COATED NANOLIPOSOME; LIPOSOME; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; ENCAPSULATION; HYDROPHILICITY; LIPID BILAYER; LIPOPHILICITY; PARTICLE SIZE; PHASE TRANSITION; PRIORITY JOURNAL; RISK ASSESSMENT; SCALE UP; SCREENING; SUSPENSION; ZETA POTENTIAL;

CHITOSAN; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPIDS; LIPOSOMES; NANOPARTICLES; SOLUBILITY;

EID: 84893269578     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.826243     Document Type: Article

References (32)

1. Amin M, Jaafari MR, Tafaghodi M. (2009). Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloid Surface B 74:225-9.
2. Benita S, Poly PA, Puisieux F, Delattre, J. (1984). Radiopaque liposomes: effect of formulation conditions on encapsulation efficiency. J Pharm Sci 73:1751-5.
3. Bolhuis G, Duineveld CAA, Boer JH, Coenegracht PMJ. (1995). Simultaneous optimization of multiple criteria in tablet formulation: part I. Pharm Technol Eur 8:42-50.
4. Cabral ECM, Zollner RL, Santana MHA. (2004). Preparation and characterization of liposomes entrapping allergenic proteins. Braz J Chem Eng 21:137-46.
5. Chiraz JM, Roudayna D, Veronique A, et al. (2010). Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res 20:228-43.
6. Corvo ML, Boerman OC, Oyen WJ, et al. (2000). Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharm Res 17:600-6.
7. Fan M, Xu S, Xia S, Zhang X. (2008). Preparation of salidroside nanoliposomes by ethanol injection method and in vitro release study. Eur Food Res Technol 227:167-74.
8. Grit M, Underberg WJM, Crommelin DJA. (1993). Hydrolysis of saturated soybean phosphatidylcholine in aqueous liposome dispersions. J Pharm Sci 82:362-6.
9. Guo J, Ping Q, Jiang G, et al. (2003). Chitosan-coated liposomes: characterization and interaction with leuprolide. Int J Pharm 260: 167-73.
10. Hwang RC, Geemoules MK, Ramlose DS, Thomason CE. (1998). A systematic formulation optimization process for a generic pharmaceutical tablet. Pharm Technol 22:48-64.
11. Hwang SY, Kima HK, Choo J, et al. (2012). Effects of operating parameters on the efficiency of liposomal encapsulation of enzymes. Colloid Surface B 94:296-303.
12. ICH harmonised tripartite guideline (November 2005). Quality Risk Management Q9, 3-19.
13. ICH harmonised tripartite guideline (2005). Quality Risk Management Q9, 3-19.
14. ICH harmonised tripartite guideline (2006). Guidance for Industry, Pharmaceutical Development Q8, 6-7.
15. ICH, Draft consensus guideline: pharmaceutical development annex to Q8 (2008), 2-10.
16. Justo OR, Moraes AM. (2011). Analysis of process parameters on the characteristics of liposomes prepared by ethanol injection with a view to process scale-up: effect of temperature and batch volume. Chem Eng Res Des 8 9:785-92.
17. Kirby C, Clarke J, Gregoriadis G. (1980). Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 186:591-8.
18. Lee SC, Lee KE, Kim JJ, Lim SH. (2005). The effect of cholesterol in the liposome bilayer on the stabilization of incorporated retinol. J Liposome Res 15:157-66.
19. Lindberg NO, Lundstedt T. (1995). Application of multivariate analysis in pharmaceutical development work. Drug Dev Ind Pharm 21: 987-1007.
20. Mady MM, Darwish MM. (2010). Effect of chitosan coating on the characteristics of DPPC liposomes. J Adv Res 1:187-91.
21. Maitani Y, Soeda H, Junping W, Takayama K. (2001). Modified ethanol injection method for liposomes containing β-sitosterol β-d-glucoside. J Liposome Res 11:115-25.
22. Mennini N, Furlanetto S, Cirri M, Mura P. (2012). Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-b-cyclodextrin-PVP complex. Eur J Pharm Biopharm 80:67-75.
23. Naelapaa K, Alleso M, Kristensen HG, et al. (2008). Increasing process understanding by analyzing complex interactions in experimental data. J Pharm Sci 98:1852-61.
24. Naseem AC, Areeg AA, Shamsherb ASZ, Ziyaur R. (2012). Quality by design approach for formulation development: a case study of dispersible tablets. Int J Pharm 423:167-78.
25. +)-ATPase. Anal Biochem 62:349-64.
26. Szoka FC. (1996). Preparation of liposome and lipid complex compositions. United States Patent 5549910.
27. Szoka F, Papahadjopoulos D. (1978). Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75:4194-8.
28. Trummer BJ, Iyer V, Iyer SVB, et al. (2012). Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib. J Pharm Sci 101:2763-76.
29. Voinovich D, Campisi B, Moneghini M, et al. (1999). Screening of high shear mixer melt granulation process variables using an asymmetrical factorial design. Int J Pharm 190:73-81.
30. Woodle MC. (1995). Sterically stabilized liposome therapeutics. Adv Drug Deliv Rev 16:249-65.
31. Xu X, Khan MA, Burgess DJ. (2011). A quality by design. (QbD) case study on liposomes containing hydrophilic API: I formulation, processing design and risk assessment. Int J Pharm 419:52-9.
32. Xu X, Khan MA, Burgess DJ. (2012). A quality by design. (QbD) case study on liposomes containing hydrophilic API: II Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm 423:543-53.